tradingkey.logo

Tecvayli® Monotherapy Demonstrates Superior Progression-Free And Overall Survival Versus Standard Of Care As Early As First Relapse In Patients With Multiple Myeloma Predominantly Refractory To Anti-Cd38 Therapy And Lenalidomide

ReutersJan 14, 2026 10:46 PM

- Johnson & Johnson JNJ.N:

  • TECVAYLI® MONOTHERAPY DEMONSTRATES SUPERIOR PROGRESSION-FREE AND OVERALL SURVIVAL VERSUS STANDARD OF CARE AS EARLY AS FIRST RELAPSE IN PATIENTS WITH MULTIPLE MYELOMA PREDOMINANTLY REFRACTORY TO ANTI-CD38 THERAPY AND LENALIDOMIDE

  • J&J - 71% REDUCTION IN DISEASE PROGRESSION RISK AND 40% REDUCTION IN DEATH RISK

  • J&J - TECVAYLI MONOTHERAPY SAFETY PROFILE MANAGEABLE WITH NO NEW CONCERNS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI